Opaleye Management Inc.'s Form 4 filing
Eton Pharmaceuticals, Inc.ETON · filed Jun 12, 2025
- Accession no.
- 0001641172-25-014868
- Filed
- Jun 12, 2025
- Trade date
- Jun 10, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $125.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Opaleye Management Inc.CIK 0001595855 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +5,000 | $15.82F3 | +$79,100 | 2,770,000 | Indirect | |
| Jun 10, 2025 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +2,930 | $15.82F3 | +$46,352.6 | 85,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.74 to $15.9742 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Referenced by the price of 2 transactions in Table I.